420 related articles for article (PubMed ID: 18197797)
1. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
2. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
Seino K; Motohashi S; Fujisawa T; Nakayama T; Taniguchi M
Cancer Sci; 2006 Sep; 97(9):807-12. PubMed ID: 16805854
[TBL] [Abstract][Full Text] [Related]
3. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
4. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
5. Human NKT cells express granulysin and exhibit antimycobacterial activity.
Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
[TBL] [Abstract][Full Text] [Related]
7. Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L
Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
[TBL] [Abstract][Full Text] [Related]
8. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
9. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.
Singh AK; Wilson MT; Hong S; Olivares-Villagómez D; Du C; Stanic AK; Joyce S; Sriram S; Koezuka Y; Van Kaer L
J Exp Med; 2001 Dec; 194(12):1801-11. PubMed ID: 11748281
[TBL] [Abstract][Full Text] [Related]
10. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
[TBL] [Abstract][Full Text] [Related]
11. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
12. Glycolipids as immune modulatory tools.
Lalazar G; Preston S; Zigmond E; Ben Yáacov A; Ilan Y
Mini Rev Med Chem; 2006 Nov; 6(11):1249-53. PubMed ID: 17100636
[TBL] [Abstract][Full Text] [Related]
13. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells.
Roy KC; Maricic I; Khurana A; Smith TR; Halder RC; Kumar V
J Immunol; 2008 Mar; 180(5):2942-50. PubMed ID: 18292516
[TBL] [Abstract][Full Text] [Related]
14. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
15. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand.
Kawano T; Tanaka Y; Shimizu E; Kaneko Y; Kamata N; Sato H; Osada H; Sekiya S; Nakayama T; Taniguchi M
Int Immunol; 1999 Jun; 11(6):881-7. PubMed ID: 10360961
[TBL] [Abstract][Full Text] [Related]
16. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
17. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
18. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
[TBL] [Abstract][Full Text] [Related]
19. The immunoregulatory role of CD1d-restricted natural killer T cells in disease.
van der Vliet HJ; Molling JW; von Blomberg BM; Nishi N; Kölgen W; van den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
Clin Immunol; 2004 Jul; 112(1):8-23. PubMed ID: 15207777
[TBL] [Abstract][Full Text] [Related]
20. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
